دراسة نمذجة جزيئية للتأثير المثبط لمجموعة من القلويدات على أنزيم AchE لدى الإنسان لعلاج الزهايمر

[1] T. I. Adelusi et al., “Molecular modeling in drug discovery,” Informatics in Medicine Unlocked, vol. 29, Art. no. 100880, 2022, doi: 10.1016/j.imu.2022.100880.

[2] M. J. Friedli and N. C. Inestrosa, “Huperzine A and its neuroprotective molecular signaling in Alzheimer's disease,” Molecules, vol. 26, no. 21, Art. no. 6531, 2021, doi: 10.3390/molecules26216531.

[3] K. Hsu, Y. Chen, S. Lin, and J. Yang, “iGEMDOCK: A graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis,” BMC Bioinformatics, vol. 12, suppl. 1, Art. no. S33, 2011, doi: 10.1186/1471-2105-12-S1-S33.

[4] Y. Jia et al., “Oxymatrine ameliorates agomelatine-induced hepatocyte injury through promoting proteasome-mediated CHOP degradation,” Biomedicine & Pharmacotherapy, vol. 114, Art. no. 108784, 2019, doi: 10.1016/j.biopha.2019.108784.

[5] A. E. Lohning, S. M. Levonis, B. Williams-Noonan, and S. S. Schweiker, “A practical guide to molecular docking and homology modelling for medicinal chemists,” Current Topics in Medicinal Chemistry, vol. 17, no. 18, 2017, doi: 10.2174/1568026617666170130110827.

[6] S. F. McHardy, H. L. Wang, S. V. McCowen, and M. C. Valdez, “Recent advances in acetylcholinesterase inhibitors and reactivators: An update on the patent literature (2012–2015),” Expert Opinion on Therapeutic Patents, vol. 27, no. 4, pp. 455–476, 2017, doi: 10.1080/13543776.2017.1272571.

[7] H. S. Nhan, K. Chiang, and E. H. Koo, “The multifaceted nature of amyloid precursor protein and its proteolytic fragments: Friends and foes,” Acta Neuropathologica, vol. 129, no. 1, pp. 1–19, 2014, doi: 10.1007/s00401-014-1347-z.

[8] M. Ratia et al., “Huprine X and Huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer's disease in triple transgenic mice (3xTg-AD),” Neurodegenerative Diseases, vol. 11, no. 3, pp. 129–140, 2012, doi: 10.1159/000336427.

[9] H. Salim, T. Mourad, R. Al-kurdi, D. almirand R. Al-Saleh, “Studying the effect of some compounds found in some essential oils on the penicillin-binding protein in Staphylococcus aureus, using molecular docking”, Journal of Al-Wataniya Private University, vol. 1, no. 1, pp. 214–224, Dec. 2023, doi: 10.5281/zenodo.19351711.

[10] H. salim, T. Mourad, R. Al Trkmanyand L. Arroub, “Molecular modeling study of the effect of a group of compounds extracted from some essential oils on the KAS I enzyme in tuberculosis bacteria”, Journal of Al-Wataniya Private University, vol. 2, no. 1, pp. 117–128, Jun. 2024, doi: 10.5281/zenodo.20252507.

[11] A. Stepezynska et al., “Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation,” Oncogene, vol. 20, no. 10, pp. 1193–1202, 2001, doi: 10.1038/sj.onc.1204221.

[12] L. D. S. Tascone and C. M. De Campos Bottino, “Neurobiology of neuropsychiatric symptoms in Alzheimer's disease: A critical review with a focus on neuroimaging,” Dementia & Neuropsychologia, vol. 7, no. 3, pp. 236–243, 2013, doi: 10.1590/S1980-57642013DN70300002.

[13] M. Teodoro and L. Kavraki, “Conformational flexibility models for the receptor in structure-based drug design,” Current Pharmaceutical Design, vol. 9, no. 20, pp. 1635–1648, 2003, doi: 10.2174/1381612033454595.

[14] C. Van Cauwenberghe, C. Van Broeckhoven, and K. Sleegers, “The genetic landscape of Alzheimer disease: Clinical implications and perspectives,” Genetics in Medicine, vol. 18, no. 5, pp. 421–430, 2015, doi: 10.1038/gim.2015.117.

[15] J. Zhen, Y. Dai, T. Villani, D. Giurleo, J. Simon, and Q. Wu, “Synthesis of novel flavonoid alkaloids as α-glucosidase inhibitors.”

[16] X. Zhao, D. Wu, X. Ma, J. Wang, W. Hou, and W. Zhang, “Exosomes as drug carriers for cancer therapy and challenges regarding exosome uptake,” Biomedicine & Pharmacotherapy, vol. 128, Art. no. 110237, 2020, doi: 10.1016/j.biopha.2020.110237.

[17] M. Zhong et al., “Rhynchophylline alleviates cognitive deficits in multiple transgenic mouse models of Alzheimer's disease via modulating neuropathology and gut microbiota,” Acta Pharmacologica Sinica, 2025.